IDO1 and IDO2 non-synonymous gene variants: Correlation with Crohn's disease risk and clinical phenotype

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Lee, Alexander ^a   Kanuri, Navya ^a   Zhang, Yuanhao ^b   Sayuk, Gregory S ^a,c   Li, Ellen ^d   Ciorba, Matthew A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Stony Brook University   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; KYNURENINE; TRYPTOPHAN; UNCLASSIFIED DRUG; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; INDOLEAMINE 2,3-DIOXYGENASE 2, HUMAN;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; IDO1 GENE; IDO2 GENE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDY; PROTEIN FUNCTION; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRYPTOPHAN METABOLISM; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; METABOLISM;

ADULT; CASE-CONTROL STUDIES; CROHN DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; KYNURENINE; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; TRYPTOPHAN;

EID: 84919935141     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115848     Document Type: Article

References (39)

1. Iskandar HN, Ciorba MA (2012) Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res 159: 313-325.
2. Xavier RJ, Podolsky DK (2007) Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.
3. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, et al. (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491: 119-124.
4. Cho JH, Brant SR (2011) Recent insights into the genetics of inflammatory bowel disease. Gastroenterology 140: 1704-1712.
5. Munn DH, Mellor AL (2013) Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol 34: 137-143.
6. Gupta NK, Thaker AI, Kanuri N, Riehl TE, Rowley CW, et al. (2012) Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity. Inflamm Bowel Dis 18: 1214-1220.
7. Ciorba MA (2013) Indoleamine 2,3 dioxygenase in intestinal disease. Curr Opin Gastroenterol 29: 146-152.
8. Gurtner GJ, Newberry RD, Schloemann SR, McDonald KG, Stenson WF (2003) Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125: 1762-1773.
9. Ciorba MA, Bettonville EE, McDonald KG, Metz R, Prendergast GC, et al. (2010) Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol 184: 3907-3916.
10. Thaker AI, Rao MS, Bishnupuri KS, Kerr TA, Foster L, et al. (2013) IDO1 metabolites activate beta-catenin signaling to promote cancer cell proliferation and colon tumorigenesis in mice. Gastroenterology 145: 416-425 e411-414.
11. Lob S, Konigsrainer A, Zieker D, Brucher BL, Rammensee HG, et al. (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother 58: 153-157.
12. International HapMap Project. Available: http://hapmap.ncbi.nlm.nih.gov/.
13. dbSNP: Database of single nucleotide polymorphisms (SNPs) and multiple small-scale variations that include insertions/deletions, microsatellites, and non-polymorphic variants. Available: http://www.ncbi.nlm.nih.gov/snp.
14. Arefayene M, Philips S, Cao D, Mamidipalli S, Desta Z, et al. (2009) Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity. Pharmacogenet Genomics 19: 464-476.
15. Chen H, Lee A, Bowcock A, Zhu W, Li E, et al. (2011) Influence of Crohn's disease risk alleles and smoking on disease location. Dis Colon Rectum 54: 1020-1025.
16. Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55: 749-753.
17. Zhang T, Song B, Zhu W, Xu X, Gong QQ, et al. (2012) An ileal Crohn's disease gene signature based on whole human genome expression profiles of disease unaffected ileal mucosal biopsies. PLoS One 7: e37139.
18. Schrocksnadel K, Wirleitner B, Winkler C, Fuchs D (2006) Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 364: 82-90.
19. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem 43: 2424-2426.
20. Lichtenstein GR, Hanauer SB, Sandborn WJ (2009) Management of Crohn's disease in adults. Am J Gastroenterol 104: 465-483; quiz 464, 484.
21. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B: 289-300.
22. Fowler EV, Eri R, Hume G, Johnstone S, Pandeya N, et al. (2005) TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J Med Genet 42: 523-528.
23. Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, et al. (2007) Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res 67: 7082-7087.
24. Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ (2011) Indoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem 18: 2257-2262.
25. Cader MZ, Kaser A (2013) Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 62: 1653-1664.
26. Fukunaga M, Yamamoto Y, Kawasoe M, Arioka Y, Murakami Y, et al. (2012) Studies on Tissue and Cellular Distribution of Indoleamine 2,3-Dioxygenase 2: The Absence of IDO1 Upregulates IDO2 Expression in the Epididymis. J Histochem Cytochem.
27. Metz R, Smith C, Duhadaway JB, Chandler P, Baban B, et al. (2014 [Epub ahead of print]) IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol.
28. Schroecksnadel K, Winkler C, Duftner C, Wirleitner B, Schirmer M, et al. (2006) Tryptophan degradation increases with stage in patients with rheumatoid arthritis. Clin Rheumatol 25: 334-337.
29. Choi BK, Asai T, Vinay DS, Kim YH, Kwon BS (2006) 4-1BB-mediated amelioration of experimental autoimmune uveoretinitis is caused by indoleamine 2,3-dioxygenase-dependent mechanisms. Cytokine 34: 233-242.
30. Ferdinande L, Demetter P, Perez-Novo C, Waeytens A, Taildeman J, et al. (2008) Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int J Immunopathol Pharmacol 21: 289-295.
31. Mahanonda R, Sa-Ard-Iam N, Montreekachon P, Pimkhaokham A, Yongvanichit K, et al. (2007) IL-8 and IDO expression by human gingival fibroblasts via TLRs. J Immunol 178: 1151-1157.
32. Fujigaki H, Seishima M, Saito K (2012) Posttranslational modification of indoleamine 2,3-dioxygenase. Anal Bioanal Chem 403: 1777-1782.
33. Genetic Power Calculator. Available: http://pngu.mgh.harvard.edu/~purcell/gpc/#cc-ins.Harvard.
34. Nishizawa H, Kato T, Ota S, Nishiyama S, Pryor-Koishi K, et al. (2010) Genetic variation in the indoleamine 2,3-dioxygenase gene in pre-eclampsia. Am J Reprod Immunol 64: 68-76.
35. Tardito S, Negrini S, Conteduca G, Ferrera F, Parodi A, et al. (2013) Indoleamine 2,3 dioxygenase gene polymorphisms correlate with CD8+ Treg impairment in systemic sclerosis. Hum Immunol 74: 166-169.
36. Witkiewicz AK, Costantino CL, Metz R, Muller AJ, Prendergast GC, et al. (2009) Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J Am Coll Surg 208: 781-787; discussion 787-789.
37. Cutler JA, Rush AJ, McMahon FJ, Laje G (2012) Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol 26: 360-367.
38. Beatty GL, O'Dwyer PJ, Clark J, Shi JG, Newton RC, et al. (2013) Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 31 (Abstract 3025).
39. Hatem Hussein Soliman HH, Neuger A, Noyes D, Vahanian NN, Link CJ, et al. (2012) A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies. J Clin Oncol 30 (suppl; abstr 2501)